[Comment] Impact of Adding Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer

Why It Matters

Clarifying ADT’s role in the postoperative setting will shape standard‑of‑care protocols, influencing survival outcomes and treatment costs for a large patient population.

Key Takeaways

• ADT improves survival with definitive radiotherapy for high‑risk disease
• PORT trials show inconsistent overall survival benefit from added ADT
• Short‑term ADT reduces biochemical recurrence in several phase‑3 studies
• Optimal ADT duration after prostatectomy remains unresolved
• Meta‑analyses aim to identify subgroups most benefiting from ADT

Pulse Analysis

The synergy between androgen deprivation therapy and radiotherapy has reshaped the management of high‑risk prostate cancer. ADT not only shrinks tumor volume but also modulates the androgen receptor’s control of DNA‑damage‑response pathways, enhancing radiotherapy‑induced cell death. This biological rationale underpins the clear survival advantage observed when ADT accompanies definitive external‑beam radiotherapy in the primary setting.

In the postoperative arena, however, evidence is fragmented. The GETUG‑AFU 16 trial demonstrated improved biochemical‑free survival with short‑term ADT after salvage radiotherapy, while the SPPORT study added pelvic nodal irradiation and reported modest benefits. Conversely, the RADICALS‑HD series, encompassing short‑course, no‑ADT, and long‑course arms, showed limited overall‑survival differences, sparking debate over the necessity and length of hormonal suppression after prostatectomy. Meta‑analyses integrating these trials hint at a benefit for brief ADT courses, yet heterogeneity in patient risk profiles and radiotherapy techniques complicates definitive conclusions.

For clinicians, the key question is which patients merit ADT after surgery. Emerging data suggest that men with adverse pathological features—positive margins, extracapsular extension, or high Gleason scores—derive the greatest advantage from a six‑month ADT course, balancing efficacy against hormonal side effects. Ongoing individual‑patient‑data meta‑analyses aim to refine these recommendations, potentially ushering in risk‑adapted protocols that personalize postoperative therapy while containing costs. As guidelines evolve, practitioners must stay attuned to trial updates to optimize outcomes for men navigating biochemical recurrence.